BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $74 to $200, according to analysts polled by Capital IQ....
BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $74 to $200, according to analysts polled by Capital IQ....
Jean Jacques Bienaime, Director, Chief Executive Officer, on March 10, 2023, sold 23,000 shares in Biomarin Pharmaceutical (BMRN) for $2,107,800. Following...
BioMarin Pharmaceutical (BMRN) has an average outperform rating and price target range of $74 to $200, according to analysts polled by Capital IQ. (MT...
| Address | 770 Lindaro Street San Rafael, California 94901 |
| Phone | +1.415.506.6700 |
| Number of Employees | 2,849 |
| Recent SEC Filing | 03/17/2023 4 |
| Chairman & Chief Executive Officer | Jean-Jacques Bienaimé |
| Chief Financial Officer & Executive VP-Finance | Brian R. Mueller |
| Chief Information Officer | Eduardo E. von Pervieux |
| President-Worldwide Research & Development | Henry J. Fuchs |
| Price Open | $90.01 |
| Previous Close | $90.11 |
| 52 Week Range | $70.73 - 117.77 |
| Market Capitalization | $16.9 B |
| Shares Outstanding | 186.5 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 04/26/2023 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 122.62 |
| Earnings per Share | $0.75 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.5 B |
| Net Profit Margin | 6.91% |
| Return on Equity | 3.13% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
